Search results
Asthma Triggers In Homes Can Send Kids to the ER—This Organization Is Working to Change That
Health.com· 5 days agoFor parents of children with asthma, witnessing an attack of severe symptoms can be a terrifying...
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Benzinga via Yahoo Finance· 4 days agoTuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and...
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Benzinga via AOL· 3 days agoWednesday, Sanofi SA (NASDAQ:SNY) reported results from the Phase 2 study of oral rilzabrutinib in...
Eosinophilic Asthma
Health via Yahoo News· 7 days agoConsider the following: Being 35-50 years old Having a personal or family history of asthma or other allergic conditions Smoking tobacco Diagnosis If you...
GSK’s asthma drug shows promise in reducing severe attacks
WHTC 1450 Holland· 5 days ago(Reuters) - GSK's asthma drug met its primary goal of reducing asthma attacks over a 52-week period...
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Zacks via Yahoo Finance· 3 days agoGSK’s GSK two-phase III studies, which evaluated depemokimab for treating severe asthma...
Research finds few moderate or severe asthma patients prescribed recommended inhaler regimen
Medical Xpress· 4 days agoIn the United States, ICS-formoterol inhalers include Symbicort (budesonide-formoterol) and Dulera...
GSK boasts win for depemokimab in asthma trials
Clinical Trials Arena via Yahoo Finance· 5 days agoThe two randomised, multi-centre, placebo-controlled trials investigated depemokimab in adults and adolescents with severe asthma with type 2...
Manage Your Asthma: FDA on Know Your Triggers and Treatment Options
Sierra Sun Times· 4 days agoAsthma is a chronic lung disease that causes the airways to become inflamed and narrow. Symptoms of...
GSK’s Potential Blockbuster Asthma Drug Shows Promise in Latest Trial
The Wall Street Journal· 4 days agoDepemokimab could be the first approved drug to allow a long-term dosing interval, requiring only...